Infinity Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Seth Tasker
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.4yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.8yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$43m |
| Dec 31 2022 | n/a | n/a | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | n/a | n/a | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$44m |
| Jun 30 2021 | n/a | n/a | -US$43m |
| Mar 31 2021 | n/a | n/a | -US$41m |
| Dec 31 2020 | US$1m | US$386k | -US$40m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$653k | US$368k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | n/a | n/a | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$41m |
| Dec 31 2017 | US$1m | US$320k | -US$42m |
| Sep 30 2017 | n/a | n/a | -US$57m |
| Jun 30 2017 | n/a | n/a | -US$70m |
| Mar 31 2017 | n/a | n/a | US$88k |
| Dec 31 2016 | US$404k | US$266k | -US$30m |
Compensation vs Market: Insufficient data to establish whether Seth's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Seth's compensation has increased whilst the company is unprofitable.
CEO
Seth Tasker (44 yo)
7.4yrs
Tenure
US$1,435,444
Compensation
Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 17.3yrs | US$93.08k | 0.24% € 557.4 | |
| Lead Independent Director | 11.8yrs | US$125.82k | 0.017% € 38.8 | |
| Independent Director | 5.7yrs | US$85.58k | 0.0097% € 22.7 | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Independent Director | 3.8yrs | US$83.08k | 0% € 0 | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 3.8yrs | US$759.67k | no data | |
| Chair of Clinical Advisory Board | no data | US$73.08k | 0.012% € 27.4 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
5.8yrs
Average Tenure
71yo
Average Age
Experienced Board: I3F's board of directors are considered experienced (5.8 years average tenure).